Genome Insight, a precision healthcare solutions company promoting whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, announced that it has closed a $23 million in a Series B-2 investment in its latest funding round.

The round was joined by Samsung Venture Investment Corporation, Asan Foundation, SCL Group, and Ignite Innovation. Existing investors participated in this round. This round follows a Series B investment in 2022 that also raised $23 million.